ÂÜÀòÂÒÂ×

Charles Asare is currently the VP & Head of Drug Safety at Ionis Pharmaceuticals. Charles has over 15 years of experience in the pharmaceutical industry, specializing in pharmacovigilance and medical risk management.

Asare began their career at Amgen in October 2002 as a Director of Clinical Development. In this role, they were responsible for all aspects of pharmacovigilance and risk management activities. Charles then spent two years at Genentech as a Senior Safety Science Leader before moving to Takeda Global Research & Development Center in February 2010 as a Senior Medical Director of Pharmacovigilance.

In September 2012, Asare joined Allergan as a Senior Medical Director. In this role, they were independently responsible for the proactive safety strategy and all medical safety aspects of pharmacovigilance and medical risk management for assigned compounds under development as well as marketed products. Charles remained with Allergan until October 2014 when they joined Ionis Pharmaceuticals as VP & Head of Drug Safety.

Charles Asare has a MPH from Tulane University School of Medicine and an MD from Vinnytsia National Pirogov Medical University. Charles also has GCE 'A' Level in Biology/Biological Sciences, General from Prempeh college and GCE "O" Level in Biology/Biological Sciences, General from St. Peter's Seconday School.

Some of their coworkers include Richard S. Geary - EVP, Chief Development Officer, Leo Sahelijo - VP, Translational Medicine, and John Su - VP, Biometrics. Charles Asare reports to C. Frank Bennett, EVP, Chief Scientific Officer.